A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina

Sponsor
Hoffmann-La Roche
Study ID
NCT03330886
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab — DRUG
    Atezolizumab will be administered via IV at a 1200-mg dose over 60 minutes every 3 weeks (to be reduced to 30 minutes every 3 weeks if the first dose is tolerated).

Study Details

The main purpose is to study the safety and effectiveness of atezolizumab in patients with locally advanced or metastatic urothelial carcinoma whose disease has worsened during or following platinum-containing chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before (neoadjuvant) or after (adjuvant) surgical treatment in common clinical practice settings in Argentina.

Key Dates

First listed
Nov 6, 2017
Start date
Feb 9, 2018
Status verified
Mar 2023
Primary completion
Mar 2, 2019
Completion
Mar 2, 2019

Study Design

Enrollment
13 participants (actual)

Primary Outcome Measure

Percentage of Participants with Adverse Events (AE) [ Time Frame: Up to approximately 2 years. ]

Find similar trials

Nationwide
Bladder cancer trialsOncology trialsUrology trials

Related Studies